EWNYQHealthcare·Medical Devices#5 in industry

Edwards Lifesciences Corporation

Reports in 88d· 2026-07-23

+1.1% · 90d

$84.50

+0.35 (+0.41%)

News

(1)

April 2026

Apr 23, 20264 days ago8-KHealthcare

EW Raises 2026 Guidance After Strong Q1 Earnings

EWEdwards Lifesciences Corp

# 🧾 What This Document Is This is an **earnings release** – a quarterly report card for investors. Edwards Lifesciences is telling the world how much money it made, spent, and earned from January to March 2026. It’s also updating its predictions for the rest of the year. 👉 **Key takeaway:** The co

Read summaryView on SEC EDGAR

Key Data

Market Cap$48.71B

Open$83.54

Prev Close$84.15

Day Range$83.25 – $84.79

52W Range$72.30 – $87.89

Volume3,663,270

P/E (TTM)46.68

EPS$1.81

Dividend Yield—

Beta0.94

Profit Margin17.39%

Revenue Growth16.70%

Price Target$96.96(+14.8%)

Next Earnings2026-07-23(88d)

Analyst Ratings

Strong Buy30 analysts

Buy 22Hold 8Sell 0

About

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Healthcare · Medical Devices

16,000 employees

www.edwards.com